Ontralfy is a drug owned by Fidelity Biopharma Co Usa. It is protected by 1 US drug patent filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 07, 2042. Details of Ontralfy's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12042484 | Tizanidine liquid preparation and use thereof |
May, 2042
(17 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Ontralfy is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ontralfy's family patents as well as insights into ongoing legal events on those patents.
Ontralfy's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ontralfy's generic launch date based on the expiry of its last outstanding patent is estimated to be May 07, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ontralfy Generic API suppliers:
Tizanidine Hydrochloride is the generic name for the brand Ontralfy. 24 different companies have already filed for the generic of Ontralfy, with Ani Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ontralfy's generic
Alternative Brands for Ontralfy
There are several other brand drugs in the same treatment category as Ontralfy. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Metacel Pharms Llc |
| |||
About Ontralfy
Ontralfy is a drug owned by Fidelity Biopharma Co Usa. Ontralfy uses Tizanidine Hydrochloride as an active ingredient. Ontralfy was launched by Fidelity Biopharma in 2024.
Approval Date:
Ontralfy was approved by FDA for market use on 12 December, 2024.
Active Ingredient:
Ontralfy uses Tizanidine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Tizanidine Hydrochloride ingredient
Dosage:
Ontralfy is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 2MG BASE/5ML | SOLUTION | Prescription | ORAL |